Canadian Pharmacy Pipeline
Click graphic to enlarge
AQX-1125 is our clinical stage product candidate. While we believe there is an expansive list of potential clinical indications that could potentially benefit from treatment with AQX-1125, we selected COPD and BPS/IC for further Phase 2 evaluation. In addition, we have several other candidates that also target SHIP1 and that have both similar and distinct properties from AQX-1125, with some showing preliminary evidence of enhanced anti-inflammatory properties. The development status of our product candidates is summarized in the above graphic.